Pulmonary arterial hypertension (PAH) is an obstructive pulmonary vasculopathy,
characterized by excess proliferation, apoptosis resistance, inflammation, fibrosis, and
vasoconstriction. Although PAH therapies target some of these vascular abnormalities
(primarily vasoconstriction), most do not directly benefit the right ventricle (RV). This is
suboptimal because a patient's functional state and prognosis are largely determined by the
success of the adaptation of the RV to the increased afterload. The RV initially hypertrophies …